Citigroup Reaffirms Sell Rating for Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health (NYSE:HIMS)‘s stock had its “sell” rating reissued by research analysts at Citigroup in a research note issued to investors on Thursday,Benzinga reports. They presently have a $27.00 price objective on the stock. Citigroup’s target price would indicate a potential downside of 25.03% from the stock’s previous close.

A number of other research firms have also weighed in on HIMS. Canaccord Genuity Group upped their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. Piper Sandler increased their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Truist Financial increased their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Stock Up 4.7 %

Shares of NYSE:HIMS opened at $36.01 on Thursday. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98. The stock has a market cap of $8.00 billion, a P/E ratio of 81.85 and a beta of 1.37. The business’s 50 day moving average is $37.45 and its 200 day moving average is $27.31.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 78,127 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74. Following the sale, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at approximately $3,256,896.72. This trade represents a 41.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Oluyemi Okupe sold 18,959 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $25.77, for a total value of $488,573.43. Following the sale, the chief financial officer now directly owns 132,578 shares in the company, valued at $3,416,535.06. This represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,062,011 shares of company stock valued at $36,892,724. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently modified their holdings of the business. IronOak Wealth LLC. acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $922,000. Kilter Group LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $1,053,000. Cim LLC grew its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after acquiring an additional 694 shares during the period. Jefferies Financial Group Inc. acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $4,900,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $200,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.